NYSE:EWMedical Equipment
How Edwards’ TAVR-First Pivot And JenaValve Exit At Edwards Lifesciences (EW) Has Changed Its Investment Story
In recent weeks, Edwards Lifesciences has drawn attention after exiting its planned JenaValve acquisition, raising 2026 EPS guidance, and emphasizing growth in its Transcatheter Aortic Valve Replacement (TAVR) and mitral platforms amid robust demand for structural heart procedures.
An interesting angle for investors is how analysts’ upgraded views have clustered around the same theme: TAVR now anchors the company’s long-term focus, with internal platforms prioritized over external...